(Reuters) – Catalent Inc, controlled by Blackstone Group LP, said it expects its initial public offering to be priced between $19 and $22 per share, valuing the health technology company at about $2.57 billion at the top end.
Catalent’s IPO of 42.5 million shares is expected to raise about $935 million at the top end of the expected price range.
The company provides advanced delivery technologies for drugs, biologics and consumer health products.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.